Sanofi (France)
Parent Company
174/180 Avenue de France
Paris
Cedex
75013
France
Tel: 33-1-53-77-4000
Website: http://www.sanofi-synthelabo.fr/
1839 articles with Sanofi (France)
-
May is a busy month for the U.S. Food and Drug Administration (FDA)’s calendar for new drug reviews. Here’s a look.
-
BioSpace takes an in-depth look at the Top 25 of Q1.
-
Clinical Catch-Up: April 26-30
5/3/2021
Although clinical trial news related to COVID-19 was slow last week, there’s quite a bit of news on studies for other indications. -
2021 COVID-19 News: COVID-19 Possible Spread in Vehicles, US to Share AZ's COVID-19 Vaccine Globa...
4/27/2021
Please check out the biopharma industry's COVID-19 stories that are trending for April 27, 2021. -
Sanofi will use its manufacturing capabilities to support the development of 200 million doses of the Moderna COVID-19 vaccine beginning in September.
-
AstraZeneca and Sanofi announced that their MELODY Phase III trial of nirsevimab hit the primary endpoint in medically attended lower respiratory tract infections (LRTI) caused by RSV in healthy late preterm and term infants.
-
Executives at pharmaceutical companies are known for receiving large salaries. When bonuses and stock options are factored into the picture, their annual compensation can jump into the range of tens of millions of dollars, like Pfizer’s Albert Bourla, Alex Gorsky from Johnson & Johnson, and Astra...
-
The new factory will include cutting-edge technology, allowing production of three to four vaccines simultaneously, a massive improvement on the current limitation of one vaccine in an industrial site.
-
Tidal Therapeutics, which does not even have a website, came out of LabCentral in Cambridge. It focuses on developing nanoparticles able to deliver messenger RNA (mRNA) that can reprogram immune cells.
-
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
-
The U.S. Food and Drug Administration approved two new treatments for multiple myeloma and pulmonary hypertension.
-
Clinical Catch-Up: March 15-19
3/22/2021
It was a relatively quiet week in terms of clinical trial news, but there were some significant releases. Here’s a look. -
Sanofi and Regeneron Halt Cervical Cancer Trial Early Due to Dazzling Results, Plan to Submit to ...
3/15/2021
Sanofi and Regeneron Pharmaceuticals’ checkpoint inhibitor Libtayo (cemiplimab) performed so well in the companies’ Phase III clinical trial in cervical cancer that the Independent Data Monitoring Committee (IDMC) recommended the trial be halted early. They plan to use the data for regulatory sub... -
COVID-19 Vaccine News: Novavax Effective Against Variants; Sanofi/Translate Begin Early Trials
3/12/2021
While existing vaccines are being rolled out worldwide, Novavax’s is demonstrating effectiveness in late-stage trials and the partnership of Sanofi and Translate Bio is beginning early-stage trials for their mRNA vaccine. -
The biopharma industry remained strong, as demand for COVID-related products skyrocketed. However, some companies are facing layoffs. Here's a brief overview.
-
On Monday, the companies announced their checkpoint inhibitor Libtayo (cemiplimab-rwlc) won Food and Drug Administration approval for lung cancer.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for February 23, 2021.
-
The retooled COVID-19 vaccine promised by GlaxoSmithKline and vaccine giant Sanofi is entering Phase IIb testing, with new antigen dosages it hopes will boost the lackluster immune response seen in adults 50 and over during its last Phase I/II trial.
-
The companies have announced their intent to appeal the decision.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for February 16, 2021.